A researcher's view

Area of Science:

• Regulatory Science
• Dental Public Health
• Pharmaceutical Regulation

Background:

• The Food and Drug Administration (FDA) plays a crucial role in ensuring the safety and efficacy of healthcare products.
• The regulation of dental drug products by the FDA has been perceived as inflexible and slow to incorporate new scientific information.

Purpose of the Study:

• To evaluate the FDA's regulatory approach to dental drug products in light of current scientific advancements.
• To compare the FDA's regulatory function with the American Dental Association's (ADA) product acceptance programs.

Main Methods:

• Qualitative assessment of the FDA's regulatory stance on dental therapeutics.
• Review of the ADA's Council on Dental Therapeutics' processes for product evaluation and acceptance.
• Comparative analysis of regulatory effectiveness and responsiveness to scientific research.

Main Results:

• The FDA's regulatory framework for dental drugs has not adequately adapted to new scientific evidence, attributed to agency size, insufficient dental expertise, and outdated research engagement.
• The ADA's voluntary acceptance and certification programs demonstrate a consistent ability to stay current with dental research and public health issues.
• The ADA's Council on Dental Therapeutics effectively utilizes expert consultation to ensure product safety and efficacy.

Conclusions:

• The FDA faces challenges in intelligently regulating dental drug products due to internal limitations.
• The ADA's proactive and expert-driven approach provides a robust model for ensuring the safety and effectiveness of dental products.
• Both regulatory bodies contribute to protecting public oral health, but the FDA requires modernization.